MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Form 10-Q — Aug 7, 2026
Maravai LifeSciences reported Q2 2026 revenue of $51.4 million, up 8.5% year over year, with the net loss attributable to the company narrowing sharply to $12.4 million ($0.08 per Class A share) from $39.6 million a year earlier. Adjusted EBITDA swung to a positive $8.7 million from negative $10.4 million in Q2 2025. First-half 2026 revenue rose 24.4% to $117.3 million, boosted by $14.3 million of high-volume CleanCap orders for commercial-phase COVID-19 vaccine programs booked in Q1. Excluding COVID CleanCap revenue, TriLink base revenue grew 13.4%, and Q2 gross margin expanded to 40.1% from 16.4% on savings from the 2025 Corporate Realignment Plan.
Key figures
- Revenue
- 51442000
- Total Debt
- 150000000
- Debt Amount
- 150000000
- Revenue Yoy
- 8.5% (Q2); 24.4% (H1)
- Cash Position
- 70091000
- Interest Rate
- Term SOFR + 5.00% per annum (0.75% floor) or alternate base rate + 4.00%
- Maturity Date
- June 2, 2032
- Shares Outstanding
- 148,989,545 Class A and 110,684,080 Class B as of July 31, 2026
- Gtcr Voting Power
- 50.4%
- Six Month Revenue
- 117279000
- Gross Margin Q2 2026
- 40.1% vs 16.4% prior year (+2,370 bps)
- Prior Term Loan Repaid
- 294240000
- Cygnus Revenue Q2 2026
- 16773000
- Restructuring H1 2026
- 2845000
- Adjusted Ebitda Q2 2026
- 8674000
- Trilink Revenue Q2 2026
- 34669000
- Revolving Credit Facility
- 30000000
- Operating Cash Flow H1 2026
- 12657000
- Covid Clean Cap Revenue Q1 2026
- 14300000
- Loss On Debt Extinguishment H1 2026
- 3413000
Price after filing
Close on the filing date to close N calendar days later (from $6.41). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.